Cargando…
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699990/ https://www.ncbi.nlm.nih.gov/pubmed/31263284 http://dx.doi.org/10.1038/s41591-019-0495-2 |
_version_ | 1783444778810081280 |
---|---|
author | Depommier, Clara Everard, Amandine Druart, Céline Plovier, Hubert Van Hul, Matthias Vieira-Silva, Sara Falony, Gwen Raes, Jeroen Maiter, Dominique Delzenne, Nathalie M. de Barsy, Marie Loumaye, Audrey Hermans, Michel P. Thissen, Jean-Paul de Vos, Willem M. Cani, Patrice D. |
author_facet | Depommier, Clara Everard, Amandine Druart, Céline Plovier, Hubert Van Hul, Matthias Vieira-Silva, Sara Falony, Gwen Raes, Jeroen Maiter, Dominique Delzenne, Nathalie M. de Barsy, Marie Loumaye, Audrey Hermans, Michel P. Thissen, Jean-Paul de Vos, Willem M. Cani, Patrice D. |
author_sort | Depommier, Clara |
collection | PubMed |
description | Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-related disorders(2). In humans, studies have provided evidence for a negative correlation between Akkermansia muciniphila abundance and overweight, obesity, untreated T2DM, or hypertension(3–8). As the administration of A.muciniphila has never been investigated in humans, we conducted a randomized double-blind placebo-controlled pilot study in overweight/obese insulin resistant volunteers, 40 were enroled and 32 completed the trial. The primary endpoints were on safety, tolerability and metabolic parameters (i.e., insulin resistance, circulating lipids, visceral adiposity, body mass). The secondary outcomes were the gut barrier function (i.e., plasma lipopolysacharrides (LPS) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 10(10) bacteria either alive or pasteurized A.muciniphila for 3 months was safe and well tolerated. Compared to the Placebo, pasteurized A.muciniphila improved insulin sensitivity (+28.62±7.02%, P=0.002), reduced insulinemia (-34.08±7.12%, P=0.006) and plasma total cholesterol (-8.68±2.38%, P=0.02). Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group, and fat mass (-1.37±0.82kg, P=0.092) and hip circumference (-2.63±1.14cm, P = 0.091) as compared to baseline. After 3 months of supplementation, A.muciniphila reduced the levels of relevant blood markers of liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (NCT02637115) shows that the intervention was safe and well-tolerated and that the supplementation with A.muciniphila improves several metabolic paramaters. |
format | Online Article Text |
id | pubmed-6699990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-66999902020-01-01 Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Depommier, Clara Everard, Amandine Druart, Céline Plovier, Hubert Van Hul, Matthias Vieira-Silva, Sara Falony, Gwen Raes, Jeroen Maiter, Dominique Delzenne, Nathalie M. de Barsy, Marie Loumaye, Audrey Hermans, Michel P. Thissen, Jean-Paul de Vos, Willem M. Cani, Patrice D. Nat Med Article Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus (T2DM)(1). The gut microbiota is considered as a new key contributor involved in the onset of obesity-related disorders(2). In humans, studies have provided evidence for a negative correlation between Akkermansia muciniphila abundance and overweight, obesity, untreated T2DM, or hypertension(3–8). As the administration of A.muciniphila has never been investigated in humans, we conducted a randomized double-blind placebo-controlled pilot study in overweight/obese insulin resistant volunteers, 40 were enroled and 32 completed the trial. The primary endpoints were on safety, tolerability and metabolic parameters (i.e., insulin resistance, circulating lipids, visceral adiposity, body mass). The secondary outcomes were the gut barrier function (i.e., plasma lipopolysacharrides (LPS) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 10(10) bacteria either alive or pasteurized A.muciniphila for 3 months was safe and well tolerated. Compared to the Placebo, pasteurized A.muciniphila improved insulin sensitivity (+28.62±7.02%, P=0.002), reduced insulinemia (-34.08±7.12%, P=0.006) and plasma total cholesterol (-8.68±2.38%, P=0.02). Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group, and fat mass (-1.37±0.82kg, P=0.092) and hip circumference (-2.63±1.14cm, P = 0.091) as compared to baseline. After 3 months of supplementation, A.muciniphila reduced the levels of relevant blood markers of liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (NCT02637115) shows that the intervention was safe and well-tolerated and that the supplementation with A.muciniphila improves several metabolic paramaters. 2019-07-01 2019-07-01 /pmc/articles/PMC6699990/ /pubmed/31263284 http://dx.doi.org/10.1038/s41591-019-0495-2 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Depommier, Clara Everard, Amandine Druart, Céline Plovier, Hubert Van Hul, Matthias Vieira-Silva, Sara Falony, Gwen Raes, Jeroen Maiter, Dominique Delzenne, Nathalie M. de Barsy, Marie Loumaye, Audrey Hermans, Michel P. Thissen, Jean-Paul de Vos, Willem M. Cani, Patrice D. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title_full | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title_fullStr | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title_full_unstemmed | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title_short | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
title_sort | supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699990/ https://www.ncbi.nlm.nih.gov/pubmed/31263284 http://dx.doi.org/10.1038/s41591-019-0495-2 |
work_keys_str_mv | AT depommierclara supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT everardamandine supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT druartceline supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT plovierhubert supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT vanhulmatthias supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT vieirasilvasara supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT falonygwen supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT raesjeroen supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT maiterdominique supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT delzennenathaliem supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT debarsymarie supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT loumayeaudrey supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT hermansmichelp supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT thissenjeanpaul supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT devoswillemm supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy AT canipatriced supplementationwithakkermansiamuciniphilainoverweightandobesehumanvolunteersaproofofconceptexploratorystudy |